Atrás
Precio Evommune Inc (EVMN)
Gráfico del Precio de Acciones EVMN
EVMN Financiero
Evommune Inc
$31.14
-1.34%
$-0.42
Hasta hoy:Feb 17, 13:45:28 GMT-5
Ingreso
Balance general
Flujo de efectivo
Anual
Trimestral
EVMN Ingreso
Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Follow-Up Questions
¿Cuáles son los estados financieros clave de Evommune Inc?
¿Cuáles son los ratios financieros clave para EVMN?
¿Cómo se desglosan los ingresos de Evommune Inc por segmento o geografía?
¿Es rentable Evommune Inc?
¿Tiene Evommune Inc alguna deuda?
¿Cuántas acciones en circulación tiene Evommune Inc?
Estadísticas clave
Cierre Anterior
$31.57
Precio de apertura
$31.35
Rango del día
$30.21 - $33.1
Rango de 52 semanas
$13.88 - $33.2
Volumen
303.0K
Volumen promedio
534.9K
EPS (TTM)
-5.08
Rendimiento de dividendos
--
Cap. de mercado
$981.6M
¿Qué es EVMN?
Evommune, Inc. is a clinical-stage biotechnology company. The company is headquartered in Palo Alto, California and currently employs 45 full-time employees. The company went IPO on 2025-11-06. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The firm's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The firm's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.
Características
© 2026 Finture Development Limited. Todos los derechos reservados.